<DOC>
	<DOCNO>NCT00003741</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient refractory anaplastic large cell lymphoma Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Refractory Anaplastic Large Cell Lymphoma Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability multiple dose monoclonal antibody HeFi-1 patient CD30+ anaplastic large cell lymphoma Hodgkin 's lymphoma . - Determine pharmacokinetics drug patient population . - Evaluate efficacy , term correlate immunologic parameter immunogenicity , drug patient . OUTLINE : This open-label , dose-escalation study . Patients receive monoclonal antibody HeFi-1 IV 30 minute 3 time week 2 week . Treatment may continue 2 additional week absence anti-HeFi-1 response . Responding patient may continue treatment monthly interval one year . Cohorts 3-4 patient receive escalate dos monoclonal antibody HeFi-1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 4 patient experience dose-limiting toxicity . Patients follow monthly . PROJECTED ACCRUAL : A total 9 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD30+ anaplastic large cell lymphoma ( ALCL ) Hodgkin 's lymphoma At least 50 % malignant cell must react HeFi1 HIV positive HIV negative Measurable disease No symptomatic CNS disease Must fail ineligible standard chemotherapy regimen PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : More 2 month Hematopoietic : Not specify Hepatic : No significant hepatic disease Bilirubin great 2 mg/dL Renal : No significant renal disease Creatinine great 3 mg/dL Cardiovascular : No significant cardiovascular disease Pulmonary : No significant pulmonary disease Other : No significant endocrine , rheumatologic , allergic disease No active clinical disease cause cytomegalovirus ( CMV ) , herpes simplex virus ( HSV ) I , HSV II , hepatitis B , tuberculosis Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine antibody therapy Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy measurable disease Surgery : Not specify Other At least 4 week since prior cytotoxic therapy measurable disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>